Research programme: plant-derived antibiotics - 21st Century Therapeutics/Oxford Pharmaceuticals

Drug Profile

Research programme: plant-derived antibiotics - 21st Century Therapeutics/Oxford Pharmaceuticals

Alternative Names: Anti-methicillin-resistant staphylococcus aureus antibiotic - 21st Century Therapeutics/Oxford Pharmaceuticals; Anti-MRSA antibiotic - 21st Century Therapeutics/Oxford Pharmaceuticals; Botanical antibiotic - 21st Century Therapeutics; KCR; Natural product antibiotics - 21st Century Therapeutics

Latest Information Update: 25 Aug 2016

Price : $50

At a glance

  • Originator Oxford Pharmaceuticals
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top